News

Dutch grant ‘’MIT Haalbaarheidssubsidie’’ for further development of micro-SCY™ technology

July 08, 2024

Micro-SCY™ is an in-house developed, highly innovative method to screen antibody-antigen interactions in a biochemically relevant environment.

read post

Future Diagnostics wishes you happy holidays

December 19, 2023

Our company is closed on Monday December 26th, 2022. Standard opening hours apply on all other days.

read post

New Publication

August 31, 2022

Another critical step towards the clinical use of free 25OH Vitamin D measurement, as a marker for evaluating Vitamin D deficiency, has been recently published by Kerry Jones et al. Future Diagnostics is proud to be one of the authors who made this happen.

read post

New Publication

July 22, 2022

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has once more emphasized the urgent need for accurate and fast point-of-care (POC) diagnostics for outbreak control and prevention. The main challenge in the development of POC in Vitro diagnostics (IVD)is to combine a short time to result with high sensitivity, and to keep the testing cost-effective. Future Diagnostics was happy to contribute to the realization of the publication.

read post

Press release: Future Diagnostics celebrates 25th anniversary

May 16, 2022

On Friday, May 20, Future Diagnostics will celebrate its 25th anniversary. The company, which develops diagnostic tests on behalf of international biotech companies, will open its doors to invited guests that day. For a snack and a drink, the unveiling of its new logo and a tour of the laboratory in Wijchen.

read post

Re-certification ISO13485:2016

November 08, 2021

Future Diagnostics proudly received the re-certification of ISO13485:2016 for the next 3 years. Zero non-conformities were found.

read post

Development of Photonic Biosensor Device

March 23, 2021

Together with the BioCDx consortium, Future Diagnostics has been proudly working on the development of a miniaturized, reliable biosensing system for accurate and highly sensitive detection of protein cancer biomarkers, for the treatment monitoring of cancer disease and the therapeutics response.

read post

Future Diagnostics Enters Agreement with DIAsource Immunoassays for Free 25OH Vitamin D ELISA product

July 10, 2020

DIAsource Immunoassays (Louvain-la-Neuve, Belgium), a BioVendor group company, has entered into a strategic agreement with Future Diagnostics (Wijchen, The Netherlands) under which Future Diagnostics will transfer all assets, with the exclusion of IP, related to Free 25OH Vitamin D ELISA product to DIAsource, securing its continued production and sales.

read post